Literature DB >> 19116269

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.

Anna Dubrovska1, Sungeun Kim, Richard J Salamone, John R Walker, Sauveur-Michel Maira, Carlos García-Echeverría, Peter G Schultz, Venkateshwar A Reddy.   

Abstract

Characterization of the molecular pathways that are required for the viability and maintenance of self-renewing tumor-initiating cells may ultimately lead to improved therapies for cancer. In this study, we show that a CD133(+)/CD44(+) population of cells enriched in prostate cancer progenitors (PCaPs) has tumor-initiating potential and that these progenitors can be expanded under nonadherent, serum-free, sphere-forming conditions. Cells grown under these conditions have increased in vitro clonogenic and in vivo tumorigenic potential. mRNA expression analysis of cells grown under sphere-forming conditions, compared with long-term monolayer cultures, revealed preferential activation of the PI3K/AKT signaling pathway. PI3K p110alpha and beta-protein levels were higher in cells grown under sphere-forming conditions, and phosphatase and tensin homolog (PTEN) knockdown by shRNA led to an increase in sphere formation as well as increased clonogenic and tumorigenic potential. Similarly, shRNA knockdown of FoxO3a led to an increase in tumorigenic potential. Consistent with these results, inhibition of PI3K activity by the dual PI3K/mTOR inhibitor NVP-BEZ235 led to growth inhibition of PCaPs. Taken together, our data strongly suggest that the PTEN/PI3K/Akt pathways are critical for prostate cancer stem-like cell maintenance and that targeting PI3K signaling may be beneficial in prostate cancer treatment by eliminating prostate cancer stem-like cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116269      PMCID: PMC2629188          DOI: 10.1073/pnas.0810956106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

2.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

Authors:  Gabriela Dontu; Wissam M Abdallah; Jessica M Foley; Kyle W Jackson; Michael F Clarke; Mari J Kawamura; Max S Wicha
Journal:  Genes Dev       Date:  2003-05-15       Impact factor: 11.361

Review 3.  FOXO transcription factors in cell-cycle regulation and the response to oxidative stress.

Authors:  Yoko Furukawa-Hibi; Yosuke Kobayashi; Chen Chen; Noboru Motoyama
Journal:  Antioxid Redox Signal       Date:  2005 May-Jun       Impact factor: 8.401

Review 4.  Cancer stem cell biology: from leukemia to solid tumors.

Authors:  Craig T Jordan
Journal:  Curr Opin Cell Biol       Date:  2004-12       Impact factor: 8.382

5.  DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein.

Authors:  Hien Tran; Anne Brunet; Jill M Grenier; Sandeep R Datta; Albert J Fornace; Peter S DiStefano; Lillian W Chiang; Michael E Greenberg
Journal:  Science       Date:  2002-04-19       Impact factor: 47.728

6.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.

Authors:  T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

7.  CD133, a novel marker for human prostatic epithelial stem cells.

Authors:  Gavin D Richardson; Craig N Robson; Shona H Lang; David E Neal; Norman J Maitland; Anne T Collins
Journal:  J Cell Sci       Date:  2004-06-29       Impact factor: 5.285

8.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Authors:  Sauveur-Michel Maira; Frédéric Stauffer; Josef Brueggen; Pascal Furet; Christian Schnell; Christine Fritsch; Saskia Brachmann; Patrick Chène; Alain De Pover; Kevin Schoemaker; Doriano Fabbro; Daniela Gabriel; Marjo Simonen; Leon Murphy; Peter Finan; William Sellers; Carlos García-Echeverría
Journal:  Mol Cancer Ther       Date:  2008-07-07       Impact factor: 6.261

9.  Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line.

Authors:  Toru Kondo; Takao Setoguchi; Tetsuya Taga
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-07       Impact factor: 11.205

10.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

View more
  243 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  IQGAP1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation by Akt activation.

Authors:  Feng Chen; Hai Hong Zhu; Lin Fu Zhou; Shan Shan Wu; Jing Wang; Zhi Chen
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

Review 3.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

4.  Arsenic, stem cells, and the developmental basis of adult cancer.

Authors:  Erik J Tokar; Wei Qu; Michael P Waalkes
Journal:  Toxicol Sci       Date:  2010-11-11       Impact factor: 4.849

Review 5.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

6.  SLUG is a direct transcriptional repressor of PTEN tumor suppressor.

Authors:  Berna Uygur; Katrina Abramo; Evgenia Leikina; Calvin Vary; Lucy Liaw; Wen-Shu Wu
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

7.  HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.

Authors:  Yan Zhou; Jiyuan Yang; Johng S Rhim; Jindřich Kopeček
Journal:  J Control Release       Date:  2013-09-14       Impact factor: 9.776

8.  Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-catenin Pathway.

Authors:  Hyeon Jeong Lee; Jie Li; Renee E Vickman; Junjie Li; Rui Liu; Abigail C Durkes; Bennett D Elzey; Shuhua Yue; Xiaoqi Liu; Timothy L Ratliff; Ji-Xin Cheng
Journal:  Mol Cancer Res       Date:  2018-03-15       Impact factor: 5.852

9.  Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.

Authors:  Yan Zhou; Jiyuan Yang; Rui Zhang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2014-12-03       Impact factor: 5.571

10.  Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.

Authors:  P-P Liu; J Liao; Z-J Tang; W-J Wu; J Yang; Z-L Zeng; Y Hu; P Wang; H-Q Ju; R-H Xu; P Huang
Journal:  Cell Death Differ       Date:  2013-10-04       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.